Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate ... colorectal cancer and adenocarcinoma of the prostate, cervical cancer, HPV16 positive ...

Clear cell RCC accounts for approximately 75% of cases while the remaining non-clear ... They noted that these rates are comparable to those of ovarian cancer and pancreatic cancer, which already have ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase I for Epithelial Ovarian Cancer.